Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.

Authors:
Troll JG.

Journal:
Curr Atheroscler Rep

Publication Year: 2011

DOI:
10.1007/s11883-010-0152-1

PMCID:
PMC3018260

PMID:
21181310

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Curr Atheroscler Rep

Abbreviation: Curr Atheroscler Rep

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Vascular Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
How Will Our Practice Change After the CLEAR Outcomes Trial?
Abrahams T; Nelson AJ; Nicholls SJ. (2024) - Transparency Score: 3/6
Lipoprotein(a): from Causality to Treatment.
Kronenberg F. (2024) - Transparency Score: 3/6
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?
Surma S; Sahebkar A; Banach M. (2024) - Transparency Score: 2/6
Apheresis: What Should a Clinician Know?
Parhofer KG. (2023) - Transparency Score: 3/6
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
Giammanco A; Spina R; Cefalù AB and 1 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure J. Gregory Troll reports no potential conflict of interest relevant to this article."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025